Exelixis (EXEL) Partner Ipsen Affirms FDA Approval of CABOMETYX in Advanced RCC
Tweet Send to a Friend
Ipsen announced that its partner Exelixis, Inc. (Nasdaq: EXEL) received approval from the U.S. Food and Drug Administration (FDA) for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
